Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major

References

• Hahalis G, Kremastinos DT, Terzis G, et al. Global vasomotor dysfunction and accelerated vascular aging in β-thalassemia major. Atherosclerosis. 2008;198:448–457.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Bhattacharyya M. Antioxidant defense status of red blood cells of patients with β-thalassemia and Eβ-thalassemia. Clin Chim Acta. 2001;305:123–129.
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287.
   PubMed Web of Science ®Google Scholar
• Kassab-Chekir A, Laradi S, Ferchichi S, et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta. 2003;338:79–86.
   PubMed Web of Science ®Google Scholar
• Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron overloaded patients with β-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–263.
   PubMed Web of Science ®Google Scholar
• Adhiyanto C, Hattori Y, Yamashiro Y, et al. Oxidation status of β-thalassemia minor and Hb H disease, and its association with glycerol lysis time (GLT50). Hemoglobin. 2014;38:169–172.
   PubMed Web of Science ®Google Scholar
• Cheng ML, Ho HY, Tseng HC, et al. Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br J Haematol. 2005;128:119–127.
   PubMed Web of Science ®Google Scholar
• Chiou SS, Tsao CJ, Tsai SM, et al. Metabolic pathways related to oxidative stress in patients with hemoglobin h disease and iron overload. J Clin Lab Anal. 2014;28:261–268.
   PubMed Web of Science ®Google Scholar
• Dugaiczyk A, Law SW, Dennison OE. Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc Natl Acad Sci U S A. 1982;79:71–75.
   PubMed Web of Science ®Google Scholar
• He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992;358:209–215.
   PubMed Web of Science ®Google Scholar
• Awadallah SM, Atoum MF, Nimer NA, et al. Ischemia modified albumin: an oxidative stress marker in β-thalassemia major. Clin Chim Acta. 2012;413:907–910.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Curtis G, Rao N, et al. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. Eur J Biochem. 2001;268:42–48.
   PubMedGoogle Scholar
• Roy D, Quiles J, Gaze DC, et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92:113–114.
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Sabatine MS, et al. The search for a biomarker of cardiac ischemia. Clin Chem. 2003;49:537–539.
   PubMed Web of Science ®Google Scholar
• Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet. 2009;24:333–341.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes – review and clinical implications. Clin Chem Lab Med. 2011;49:177–184.
   PubMed Web of Science ®Google Scholar
• Borderie D, Allanore Y, Meune C, et al. High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem. 2004;50:2190–2193.
   PubMed Web of Science ®Google Scholar
• Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43:450–454.
   PubMed Web of Science ®Google Scholar
• Valle Gottlieb MG, da Cruz IB, Duarte MM. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95:586–591.
   PubMed Web of Science ®Google Scholar
• Piva SJ, Duarte MM, Da Cruz IB. Ischemia-modified albumin as an oxidative stress biomarker in obesity. Clin Biochem. 2011;44:345–347.
   PubMed Web of Science ®Google Scholar
• Kazanis K, Dalamaga M, Nounopoulos C, et al. Ischemia modified albumin, high-sensitivity c-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clin Chim Acta. 2009;408(1–2):65–69.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers. 2010;15:655–662.
   PubMed Web of Science ®Google Scholar
• Giardina PJV, Forget BG. Thalassemia syndromes. In: R Hoffman, EJ Benz, SJ Shattil, B Furie, LE Silberstein, P McGlave, H Heslop, editor. Hematology: basic principles and practice. 5th ed. Philadelphia: Elsevier Churchill Livingstone; 2008. p. 535–563.
   Google Scholar
• Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965.II. Arch Dis Child. 1966;41:613–635.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.
   PubMed Web of Science ®Google Scholar
• Vermylen C. What is new in iron overload? Eur J Pediatr. 2008;167:377–381.
   PubMed Web of Science ®Google Scholar
• Silvilairat S, Sittiwangkul R, Pongprot Y, et al. Tissue Doppler echocardiography reliably reflects severity of iron overload in pediatric patients with beta thalassemia. Eur J Echocardiogr. 2008;9:368–372.
   PubMed Web of Science ®Google Scholar
• Tantawy AA, Adly AA, Ismail EA, et al. Flow cytometric assessment of circulating platelet and erythrocytes microparticles in young thalassemia major patients: relation to pulmonary hypertension and aortic wall stiffness. Eur J Haematol. 2013;90:508–518.
   PubMed Web of Science ®Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310.
   PubMedGoogle Scholar
• Pashankar FD, Carbonella J, Bazzy-Asaad A, et al. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics. 2008;121:777–782.
   PubMed Web of Science ®Google Scholar
• Morris CR, Kim HY, Trachtenberg F, et al. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a thalassemia clinical research network report. Blood. 2011;118:3794–3802.
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530.
   PubMed Web of Science ®Google Scholar
• Dalla Pozza R, Ehringer-Schetitska D, Fritsch P, et al. Association for European paediatric cardiology working group cardiovascular prevention. Intima media thickness measurement in children: A statement from the association for European paediatric cardiology (AEPC) working group on cardiovascular prevention endorsed by the association for European paediatric cardiology. Atherosclerosis. 2015;238:380–387.
   PubMed Web of Science ®Google Scholar
• Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311–315.
   PubMed Web of Science ®Google Scholar
• Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49:581–585.
   PubMed Web of Science ®Google Scholar
• Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006;152:253–262.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Vazquez JM, Calvino R, et al. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart. 2006;92:1852–1853.
   PubMed Web of Science ®Google Scholar
• Lee E, Eom JE, Jeon KH, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal. 2014;91:17–23.
   PubMed Web of Science ®Google Scholar
• Kountana E, Tziomalos K, Semertzidis P, et al. Comparison of the diagnostic accuracy of ischemia-modified albumin and echocardiography in patients with acute chest pain. Exp Clin Cardiol Spring. 2013;18:98–100.
   PubMedGoogle Scholar
• Vyakaranam S, Bhongir AV, Patlolla D, et al. Maternal serum ischemia modified albumin as a marker for hypertensive disorders of pregnancy: a pilot study. Int J Reprod Contracept Obstet Gynecol. 2015;4:611–616.
   PubMedGoogle Scholar
• Mousa S, Afifi M, Saedii A, et al. Ischemia modified albumin in children with transfusion-dependent β-thalassemia: a new marker for an old problem. Egyptian J Haematol. 2016;41:45–49.
   Google Scholar
• Awadallah S, Al Arrayed K, Bahareth E, et al. Total antioxidant capacity and ischemia modified albumin in beta thalassemia. Clin Lab. 2013;59:687–691.
   PubMed Web of Science ®Google Scholar
• De A, Chowdhury N, Sen P, et al. Correlation of cobalt binding activity of albumin with the common markers of oxidative stress in thalassemia syndrome patients. Oxid Antioxid Med Sci. 2013;2:297–301.
   Google Scholar
• Naithani R, Chandra J, Bhattacharjee J, et al. Peroxidative stress and antioxidant enzymes in children with β-thalassemia major. Pediatr Blood Cancer. 2006;46:780–785.
   PubMed Web of Science ®Google Scholar
• Dash P, Mangaraj M, Ray S, et al. Ischaemia modified albumin-an indicator of widespread endothelial damage in diabetes mellitus. J Physiobiochem Metab. 2014;3:1.
   Google Scholar
• Bazvand F, Shams S, Borji Esfahani M, et al. Total antioxidant status in patients with major β-thalassemia. Iran J Pediatr. 2011;21:159–165.
   PubMed Web of Science ®Google Scholar
• Sultana N, Sadiya S, Rahman MH. Correlation between serum bilirubin and serum ferritin level in thalassaemia patients. Bangladesh J Med Biochem. 2011;4:6–12.
   Google Scholar
• Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002;32:55–60.
   PubMed Web of Science ®Google Scholar
• Walter PB, Macklin EA, Porter J, et al. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the novartis CICL670A0107 trial. Haematologica. 2008;93:817–825.
   PubMed Web of Science ®Google Scholar
• Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Italian J Pediatr. 2010;36:39.
   PubMed Web of Science ®Google Scholar
• Cakmak A, Soker M, Koc A, et al. Prolidase activity and oxidative status in patients with thalassemia major. J Clin Lab Analysis. 2010;24:6–11.
   PubMed Web of Science ®Google Scholar
• Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Hematologica. 2011;96:41–47.
   PubMed Web of Science ®Google Scholar
• Mokhtar GM, Gadallah M, El Sherif NH, et al. Morbidities and mortality in transfusion-dependent beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30:93–103.
   PubMed Web of Science ®Google Scholar
• Bejaoui M, Guirat N. Beta thalassemia major in a developing country: epidemiological, clinical and evolutionary aspects. Mediterr J Hematol Infect Dis. 2013;5:e201–3002.
   Google Scholar
• Hamdy AM, Zein El-Abdin MY, Abdel-Hafez MA. Right ventricular function in patients with beta thalassemia: relation to serum ferritin level. Echocard. 2007;24:795–801.
   PubMed Web of Science ®Google Scholar
• Falkensammer J, Frech A, Duschek N, et al. Prognostic relevance of ischemia-modified albumin and Nt-proBNP in patients with peripheral arterial occlusive disease. Clin Chim Acta. 2015;438:255–260.
   PubMed Web of Science ®Google Scholar
• Açıkgöz Ş, Edebali N, Barut F, et al. Ischemia modified albumin increase indicating cardiac damage after experimental subarachnoid hemorrhage. BMC Neurosci. 2014;15:33.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Koutelou M, et al. Ischaemia-modified albumin in dilated cardiomyopathy. Ann Clin Biochem. 2009;46(Pt 3):241–243.
   PubMed Web of Science ®Google Scholar
• Wood JC. Cardiac complications in thalassemia major. Hemoglobin. 2009;33(Suppl 1):S81–86.
   PubMedGoogle Scholar
• Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2010;1202:205–213.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation. 2011;123:1227–1232.
   PubMed Web of Science ®Google Scholar
• Meloni A, Detterich J, Pepe A, et al. Pulmonary hypertension in well-transfused thalassemia major patients. Blood Cells Mol Dis. 2015;54:189–194.
   PubMed Web of Science ®Google Scholar
• Can U, Yerlikaya FH, Yosunkaya S. Role of oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. J Chin Med Assoc. 2015;78:702–708.
   PubMed Web of Science ®Google Scholar
• Rooyakkers TM, Stroes ES, Kooistra MP. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest. 2002;32:9–16.
   PubMed Web of Science ®Google Scholar
• Day SM, Duquaine D, Mundada LV. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107:2601–2606.
   PubMed Web of Science ®Google Scholar
• Aggeli C, Antoniades C, Cosma C. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta-thalassemia major. Int J Cardiol. 2005;105:80–84.
   PubMed Web of Science ®Google Scholar
• Tricot O, Mallat Z, Heymes C. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation. 2000;101:2450–2453.
   PubMed Web of Science ®Google Scholar
• Kyriakou DS, Alexandrakis MG, Kyriakou ES. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol. 2001;80:577–583.
   PubMed Web of Science ®Google Scholar
• Aggoun Y, Szezepanski I, Bonnet D. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events in children. Pediatr Res. 2005;58:173–178.
   PubMed Web of Science ®Google Scholar
• Devine PJ, Carlson DW, Taylor AJ. Clinical value of carotid intima-media thickness testing. J Nucl Cardiol. 2006;13:710–718.
   PubMed Web of Science ®Google Scholar
• Kucuk A, Uslu AU, Arslan S, et al. Ischemia-modified albumin and atherosclerosis in patients with familial Mediterranean fever. Angiology. 2015;17(3):23–33.
   Google Scholar
• Yatmark P, Morales NP, Chaisri U, et al. Effects of iron chelators on pulmonary iron overload and oxidative stress in beta-thalassemic mice. Pharmacology. 2015;96:192–199.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884.
   PubMed Web of Science ®Google Scholar
• Srichairatanakool S, Fucharoen S. Antioxidants as complementary medication in thalassemia. In: F Atroshi, editor. Pharmacology and nutritional intervention in the treatment of disease. 2014. InTech, DOI: 10.5772/57372. Available from: http://www.intechopen.com/books/pharmacology-and-nutritional-intervention-in-the-treatment-of-disease/antioxidants-as-complementary-medication-in-thalassemia.
   Google Scholar
• Yanpanitch OU, Hatairaktham S, Charoensakdi R, et al. Treatment of β-thalassemia/hemoglobin E with antioxidant cocktails results in decreased oxidative stress, increased hemoglobin concentration, and improvement of the hypercoagulable state. Oxid Med Cell Longev. 2015;2015:537–954.
   Web of Science ®Google Scholar
• Elalfy MS, Saber MM, Adly AA, et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload. Eur J Haematol. 2016;96:318–326.
   PubMed Web of Science ®Google Scholar